Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission

Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as... Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 REVIEW URRENT Broadly neutralizing antibodies combined with PINION latency-reversing agents or immune modulators as strategy for HIV-1 remission a,b b Jesper Damsgaard Gunst , Jesper Falkesgaard Højen , a,b and Ole Schmeltz Søgaard Purpose of review Antiretroviral therapy (ART) is extremely effective in controlling HIV-1 infection; however, ART is not curative. Here, we review broadly neutralizing anti-HIV-1 antibodies (bNAbs) combined with latency- reversing agents (LRAs) or immune modulators as strategy for achieving long-term HIV-1 remission. Recent findings Clinical trials testing the effect of a single intervention such as a LRA ‘shock and kill’, immune modulator or bNAbs among HIV-1 infected individuals on long-term suppressive ART have not lead to long-term HIV-1 remission when ART is stopped. Novel combinations of interventions designed to eliminate infected cells and enhance immune-effector functions are being investigated. Findings in nonhuman primates (NHPs) of such combinations are very promising and clinical trials are now ongoing. These trials will provide the first indication of the efficacy of combinations of bNAbs and LRA or immune modulators for achieving durable HIV-1 remission. Summary bNAbs facilitate the elimination of HIV-1 infected cells and boost immune responses. Preclinical findings show that these effects http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Opinion in HIV & AIDS Wolters Kluwer Health

Broadly neutralizing antibodies combined with latency-reversing agents or immune modulators as strategy for HIV-1 remission

Loading next page...
 
/lp/wolters-kluwer-health/broadly-neutralizing-antibodies-combined-with-latency-reversing-agents-oDhz7iKmbL

References (53)

Publisher
Wolters Kluwer Health
Copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1746-630X
eISSN
1746-6318
DOI
10.1097/COH.0000000000000641
Publisher site
See Article on Publisher Site

Abstract

Downloaded from http://journals.lww.com/co-hivandaids by BhDMf5ePHKbH4TTImqenVJ2toCr/9wZZjwPUWvYES9l2nY+zyylnl33NGMK6MRsx on 10/02/2020 REVIEW URRENT Broadly neutralizing antibodies combined with PINION latency-reversing agents or immune modulators as strategy for HIV-1 remission a,b b Jesper Damsgaard Gunst , Jesper Falkesgaard Højen , a,b and Ole Schmeltz Søgaard Purpose of review Antiretroviral therapy (ART) is extremely effective in controlling HIV-1 infection; however, ART is not curative. Here, we review broadly neutralizing anti-HIV-1 antibodies (bNAbs) combined with latency- reversing agents (LRAs) or immune modulators as strategy for achieving long-term HIV-1 remission. Recent findings Clinical trials testing the effect of a single intervention such as a LRA ‘shock and kill’, immune modulator or bNAbs among HIV-1 infected individuals on long-term suppressive ART have not lead to long-term HIV-1 remission when ART is stopped. Novel combinations of interventions designed to eliminate infected cells and enhance immune-effector functions are being investigated. Findings in nonhuman primates (NHPs) of such combinations are very promising and clinical trials are now ongoing. These trials will provide the first indication of the efficacy of combinations of bNAbs and LRA or immune modulators for achieving durable HIV-1 remission. Summary bNAbs facilitate the elimination of HIV-1 infected cells and boost immune responses. Preclinical findings show that these effects

Journal

Current Opinion in HIV & AIDSWolters Kluwer Health

Published: Sep 1, 2020

There are no references for this article.